Related Experiment Video
Updated: Jun 5, 2025
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Intratumoral delivery of mRNA encoding the endogenous TLR2/6 agonist UNE-C1 induces immunogenic cell death and
Uijoo Kim1,2, Sunkyo Hwang2, Seongmin Cho2
1College of Pharmacy, Yonsei University, Incheon, Republic of Korea.
Introduction:
Recent investigations have highlighted the intratumoral administration of Toll-like receptor (TLR) ligands as a promising approach to initiate localized immune responses and enhance antitumor immunity. However, the clinical application of these ligands is limited by their rapid dissemination from the tumor microenvironment, raising concerns about reduced effectiveness and systemic toxicity.
Methods:
To address these challenges, our study focused on the intratumoral delivery of mRNA encoding UNE-C1, a TLR2/6 ligand known for its efficacy and low toxicity profile. We explored the potential of UNE-C1 to induce immunogenic cell death (ICD) through autocrine mechanisms, facilitated by the release of damage-associated molecular patterns (DAMPs) triggered by TLR2 activation.
Results:
Our findings indicate that sensitivity to UNE-C1-induced cell death is dependent on the expression levels of TLR2 and the Fas-associated death domain (FADD) in cancer cells. Furthermore, we investigated the paracrine activation of dendritic cells (DCs) by UNE-C1 via TLR2 signaling, which primes a CD8+ T cell response essential for tumor regression.
Discussion:
Our results advocate for the intratumoral delivery of UNE-C1 via mRNA therapy as a promising strategy for innovative antitumor treatments.
Insights
Intratumoral mRNA therapy delivering UNE-C1, a Toll-like receptor (TLR) 2/6 ligand, shows promise for cancer treatment. This approach enhances antitumor immunity by inducing cancer cell death and activating T cells, overcoming limitations of traditional TLR ligand delivery.
Area of Science:
- Immunology
- Oncology
- Molecular Therapy
Background:
- Intratumoral administration of Toll-like receptor (TLR) ligands enhances antitumor immunity.
- Clinical use of TLR ligands is limited by rapid dissemination, reducing efficacy and increasing toxicity.
Purpose of the Study:
- To investigate intratumoral mRNA delivery of UNE-C1, a TLR2/6 ligand, for cancer therapy.
- To explore UNE-C1's potential to induce immunogenic cell death (ICD) and activate anti-tumor immune responses.
Main Methods:
- Intratumoral mRNA encoding UNE-C1 delivery.
- Assessment of UNE-C1-induced cancer cell death via autocrine damage-associated molecular patterns (DAMPs) triggered by TLR2.
- Evaluation of paracrine activation of dendritic cells (DCs) and subsequent CD8+ T cell priming.
Main Results:
- UNE-C1-induced cell death sensitivity depends on cancer cell Toll-like receptor 2 (TLR2) and Fas-associated death domain (FADD) expression.
- UNE-C1 triggers TLR2 signaling in DCs, priming a CD8+ T cell response crucial for tumor regression.
Conclusions:
- Intratumoral mRNA therapy with UNE-C1 is a viable strategy for cancer treatment.
- UNE-C1 demonstrates potential for inducing localized immune responses and promoting tumor regression.
Related Concept Videos
01:27Tumor Immunotherapy
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...